Alameda, California
United States
55
2020-06-11
The entities that hold a legal rights for patent applications filed by inventor Stull Robert A.:
Robert A. Stull from Alameda, US has applied for patents for these inventions. The list has both pending applications and granted patents:
ANTI SEZ6 ANTIBODIES AND METHODS OF USE
#2 | 2020-05-07Light chain variable regions
#3 | 2019-08-15DLL3 MODULATORS AND METHODS OF USE
#4 | 2019-07-04ANTI-DLL3 DRUG CONJUGATES FOR TREATING TUMORS AT RISK OF NEUROENDOCRINE TRANSITION
#5 | 2019-03-21NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
#6 | 2019-03-14NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
#7 | 2019-02-14DLL3 MODULATORS AND METHODS OF USE
#8 | 2019-01-17NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE
#9 | 2019-01-03NOVEL ANTI-UPK1B ANTIBODIES AND METHODS OF USE
#10 | 2018-11-15NOVEL ANTI-EMR2 ANTIBODIES AND METHODS OF USE
#11 | 2018-06-14Anti-PTK7 antibodies and methods of use
#12 | 2018-02-15ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#13 | 2018-02-08Methods of delivering DLL3 antibody drug conjugates
#14 | 2018-02-08Methods of making DLL3 antibody drug conjugates
#15 | 2018-01-18Anti-DLL3 antibody drug conjugates and methods of use
#16 | 2017-12-28Anti SEZ6 antibodies and methods of use
#17 | 2017-12-28Anti-DLL3 antibody drug conjugates
#18 | 2017-11-23ANTI-CLDN CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
#19 | 2017-10-26Kits containing DLL3 antibody drug conjugates
#20 | 2017-09-28Anti-DLL3 antibody drug conjugates
#21 | 2017-09-21Anti-DLL3 antibody drug conjugates for treating cancer
#22 | 2017-09-21Methods of making DLL3 antibody drug conjugates
#23 | 2017-09-21Methods of delivering DLL3 antibody drug conjugates
#24 | 2017-09-21Anti-DLL3 antibody drug conjugates
#25 | 2017-05-04Anti-CD324 monoclonal antibodies and uses thereof
#26 | 2017-03-23Modulators and methods of use
#27 | 2017-01-05Anti-DLL3 antibody drug conjugates for treating cancer
#28 | 2016-10-06Anti-claudin antibodies and methods of use
#29 | 2016-09-22PTK7 modulators and methods of use
#30 | 2016-09-01Anti-DLL3 antibody drug conjugates
#31 | 2016-09-01Anti-DLL3 antibody drug conjugates
#32 | 2016-08-11Anti-DLL3 antibody drug conjugates
#33 | 2016-06-09Kits containing DLL3 antibody drug conjugates
#34 | 2016-06-02Methods of delivering DLL3 antibody drug conjugates
#35 | 2016-05-19Methods of making DLL3 antibody drug conjugates
#36 | 2016-05-12Multivalent DLL3 antibodies
#37 | 2016-03-17Anti-DLL3 antibodies
#38 | 2015-11-26Anti-CD324 monoclonal antibodies and uses thereof
#39 | 2015-11-19Anti-DLL3 antibody drug conjugates
#40 | 2015-11-12NOTUM PROTEIN MODULATORS AND METHODS OF USE
#41 | 2015-09-24Anti-DLL3 antibody drug conjugates and methods of use
#42 | 2015-09-15Anti-DLL3 antibody drug conjugates and methods of use
#43 | 2015-01-15Anti SEZ6 antibodies and methods of use
#44 | 2014-12-18Anti-DLL3 antibody drug conjugates for treating cancer
#45 | 2014-12-11Anti-DLL3 antibody drug conjugates
#46 | 2014-12-11Anti-DLL3 antibodies
#47 | 2014-12-11Nucleic acid encoding DLL3 antibodies
#48 | 2014-12-11Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies
#49 | 2014-12-11Anti-DLL3 antibody drug conjugates and methods of use
#50 | 2014-04-17PTK7 modulators and methods of use
#51 | 2014-04-03Modulators and methods of use
#52 | 2013-11-14Modulators and methods of use
#53 | 2013-08-29NOTUM PROTEIN MODULATORS AND METHODS OF USE
#54 | 2013-03-07Novel Modulators and Methods of Use
#55 | 2006-05-04Compositions and methods relating to angiogenesis and tumorigenesis
126935 ⎘